natgillin/translations-raw huggingface dataset:
The pharmacokinetics of palonosetron or netupitant has not been studied in subjects with end-stage renal disease requiring hemodialysis and no data on the effectiveness or safety of netupitant/palonosetron capsules in these patients are available.
Farmakokinetike palonosetrona ali netupitanta niso preučili pri osebah s končnim stadijem bolezni ledvic, ki potrebujejo hemodializo, in podatkov o učinkovitosti ali varnosti kapsul netupitanta in palonosetrona pri teh bolnikih ni na voljo.
Serotonergic medicinal products (e.g. SSRIs and SNRIs)
Serotonergična zdravila (npr. SSRI in SNRI)
M1, M2 and M3 metabolites were all shown to be pharmacologically active in an animal pharmacodynamic model, where M3 was most potent and M2 least active.
Za presnovke M1, M2 in M3 so na živalskem farmakodinamičnem modelu dokazali, da so farmakološko aktivni, pri čemer je bil M3 najbolj, M2 pa najmanj aktiven.
As use in patients with severe hepatic impairment may be associated with increased exposure of netupitant, this medicinal product should be used with caution in these patients (see sections 4.4 and
Ker je uporaba pri bolnikih s hudo okvaro jeter lahko povezana z zvečano izpostavljenostjo netupitantu, je treba to zdravilo pri teh bolnikih uporabljati previdno (glejte poglavji 4.4 in 5.2).
In a study performed in healthy volunteers, netupitant does not affect the exposure of digoxin, a P-gp substrate, whereas it increases its Cmax by 1.09 fold [90%CI 0.9-1.31].
V študiji z zdravimi prostovoljci netupitant ni vplival na izpostavljenost digoksinu, ki je substrat P-gp, pri čemer pa je povečal njegovo Cmax za 1,09-krat [90 % IZ 0,9-1,31].
• problems with the muscles in your heart (cardiomyopathy)
• težave z mišicami v srcu (kardiomiopatija),
Maximum concentrations and total exposure of netupitant were increased in subjects with mild (n=8), moderate (n=8), and severe (n=2) hepatic impairment compared to matching healthy subjects, although there was pronounced individual variability in both hepatically-impaired and healthy subjects.
Največje koncentracije in celotna izpostavljenost netupitantu so bile večje pri osebah z blago (n = 8), zmerno (n = 8) in hudo (n = 2) okvaro jeter v primerjavi z ujemajočimi se zdravimi osebami, čeprav je bila individualna variabilnost pri osebah z okvaro jeter in zdravih osebah izrazita.
(shown in blood tests)
(vidne pri krvnih preiskavah);
Appropriate observation of patients for serotonin syndrome-like symptoms is advised (see section 4.8).
Priporočamo ustrezno opazovanje bolnikov glede simptomov, podobnih kot pri serotoninskem sindromu (glejte poglavje 4.8).
In female subjects (n=18), the mean AUC was 35% higher and the mean Cmax was 26% higher than in male subjects (n=18).
Pri ženskah (n = 18) je bila povprečna AUC za 35 % višja in povprečna Cmax je bila za 26 % višja kot pri moških (n = 18).
Netupitant is not a substrate for P-gp.
Netupitant ni substrat za P-gp.
It is unknown whether palonosetron or netupitant are excreted in human milk.
Ni znano, ali se palonosetron ali netupitant izločata v materino mleko.
Caution should be exercised in patients with severe hepatic impairment since limited data are available in these patients.
Pri bolnikih s hudo okvaro jeter je potrebna previdnost, saj je za te bolnike na voljo malo podatkov.
In the ADME trial, less than 5% of all netupitant-related material was excreted in urine and less than 1% of the netupitant dose was eliminated unchanged in the urine and therefore any accumulation of netupitant or metabolites after a single dose would be negligible.
V preskušanju ADME se je manj kot 5 % vsega z netupitantom povezanega materiala izločilo v urin in manj kot 1 % odmerka netupitanta se je nespremenjenega izločilo v urin, kar pomeni, da je akumulacija netupitanta ali presnovkov po enkratnem odmerku zanemarljiva.
• modifications (or disturbances) in heart rhythm
• spremembe (ali motnje) srčnega ritma,
Palonosetron is a 5-HT3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors.
Palonosetron je antagonist receptorjev 5-HT3 z močno afiniteto k vezavi na ta receptor in malo ali nič afinitete za druge receptorje.
The primary efficacy endpoint was complete response (CR) rate (defined as no emetic episodes, no rescue medication) within 120 hours (overall phase) after the start of the highly emetogenic chemotherapy administration.
Primarni kriterij učinkovitosti je bila stopnja popolnega odziva (CR; opredeljena kot odsotnost emetičnih epizod in uporabe reševalnih zdravil) v roku 120 ur (celotna faza) po začetku dajanja zelo emetogene kemoterapije.
Hepatic impairment does not significantly affect total body clearance of palonosetron compared to the healthy subjects.
Okvara jeter nima znatnega vpliva na celoten telesni očistek palonosetrona v primerjavi z zdravimi osebami.
• The active substances are palonosetron and netupitant.
• Učinkovini sta palonosetron in netupitant.
Palonosetron soft capsule
Mehka kapsula palonosetrona
Renal excretion for netupitant is negligible.
Izločanje netupitanta prek ledvic je zanemarljivo.
All patients received a single oral dose of dexamethasone.
Vsi bolniki so prejeli enkraten peroralni odmerek deksametazona.
Netupitant/palonosetron capsules are contraindicated during pregnancy (see section 4.3).
Kapsule netupitanta in palonosetrona so kontraindicirane med nosečnostjo (glejte poglavje 4.3).
Pharmacotherapeutic group: Antiemetics and antinauseants, serotonin (5-HT3) antagonists; ATC code: A04AA55
Farmakoterapevtska skupina: Antiemetiki in zdravila proti slabosti, antagonisti serotonina (5-HT3), oznaka ATC: A04AA55
High doses of palonosetron (each dose causing at least 15 times the human therapeutic exposure) applied daily for two years caused an increased rate of liver tumors, endocrine neoplasms (in thyroid, pituitary, pancreas, adrenal medulla) and skin tumors in rats but not in mice.
Veliki odmerki palonosetrona (vsak odmerek je povzročil vsaj 15-krat večjo izpostavljenost od terapevtske izpostavljenosti pri človeku), ki so jih dve leti dajali vsak dan, so povzročili povečano stopnjo jetrnih tumorjev, endokrinih neoplazem (v ščitnici, hipofizi, trebušni slinavki ter sredici nadledvične žleze) in kožnih tumorjev pri podganah, ne pa pri miših.
The primary efficacy endpoint was the CR rate in the delayed phase, 25-120 hours after the start of the chemotherapy administration.
Primarni kriterij učinkovitosti je bila stopnja CR v zakasnjeni fazi, in sicer 25-120 ur po začetku prejemanja kemoterapije.
However, due to the large volume of distribution of palonosetron and netupitant, dialysis is unlikely to be an effective treatment for overdose.
Vendar pa zaradi velikega volumna porazdelitve palonosetrona in netupitanta ni verjetno, da bi bila dializa učinkovito zdravljenje prevelikega odmerjanja.
There are no data about the use of netupitant in pregnant women.
Podatkov o uporabi netupitanta pri nosečnicah ni.
• midazolam - a sedative used to treat anxiety
• midazolam, ki je pomirjevalo, ki se uporablja za zdravljenje anksioznosti;
However, since netupitant/palonosetron capsules contains a 5-HT3 receptor antagonist, caution should be exercised in concomitant use with medicinal products that increase the QT interval or in patients who have or are likely to develop prolongation of the QT interval.
Ker pa kapsule netupitanta in palonosetrona vsebujejo antagonist receptorjev 5-HT3, je potrebna previdnost pri sočasni uporabi z zdravili, ki podaljšujejo interval QT, ali pri bolnikih, ki so razvili podaljšan interval QT, oziroma je verjetno, da ga bodo.
No dosage adjustment is necessary for elderly patients.
Prilagoditev odmerka pri starejših bolnikih ni potrebna.
moxifloxacin, haloperidol, chlorpromazine, quetiapine, thioridazine or domperidone
moksifloksacin, haloperidol, klorpromazin, kvetiapin, tioridazin ali domperidon;
Palonosetron is eliminated by multiple routes with approximately 50% metabolized to form two primary metabolites: N-oxide-palonosetron and 6-S-hydroxy-palonosetron.
Palonosetron se izloča prek več poti, pri čemer se ga približno 50 % presnovi v dva osnovna presnovka: N-oksid-palonosetron in 6-S-hidroksi-palonosetron.
Also tell your doctor, pharmacist or nurse if you are taking any of the following medicines as your doctor may need to change the dose of these other medicines:
Zdravniku, farmacevtu ali medicinski sestri povejte tudi, če jemljete katero koli od naslednjih zdravil, saj bo zdravnik morda moral spremeniti odmerek teh zdravil:
The proportion of patients with Overall no impact on daily life was 6.3% higher (p value =0.005) in the Akynzeo group (78.5%) than in the palonosetron group (72.1%).
Delež bolnikov brez vpliva na vsakodnevno življenje v kategoriji Skupno je bil za 6,3 % večji (vrednost p = 0,005) v skupini z zdravilom Akynzeo (78,5 %) kot v skupini s palonosetronom (72,1 %).
Effect of other medicinal products on the pharmacokinetics of Akynzeo
Učinek drugih zdravil na farmakokinetiko zdravila Akynzeo
Only limited data from animal studies are available regarding the placental transfer (see section 4.6).
Iz živalskih študij je na voljo le malo podatkov o prehajanju skozi placento (glejte poglavje 4.6).
Exposure to netupitant (Cmax, AUC0-t and AUC0-∞) compared to matching healthy subjects was 11%, 28% and 19% higher in mild and 70%, 88% and 143% higher in moderate hepaticallyimpaired subjects, respectively.
Izpostavljenost netupitantu (Cmax, AUC0-t in AUC0-∞) v primerjavi z ujemajočimi se zdravimi osebami je bila za 11 %, 28 % oziroma 19 % večja pri osebah z blago okvaro jeter ter za 70 %, 88 % oziroma 143 % večja pri osebah z zmerno okvaro jeter.
Netupitant/palonosetron capsules, when given with a single oral dose of 60 μg ethinylestradiol and 300 μg levonorgestrel had no significant effect on the AUC of ethinylestradiol and increased the AUC of levonorgestrel by 1.4-fold; clinical effects on the efficacy of hormonal contraception are unlikely.
Kapsule netupitanta in palonosetrona ob dajanju z enkratnim peroralnim odmerkom 60 μg etinilestradiola in 300 μg levonorgestrela ni imelo znatnega učinka na AUC etinilestradiola in je povečalo AUC levonorgestrela za 1,4-krat; klinični učinki na učinkovitost hormonske kontracepcije niso verjetni.
Therefore, patients with known hypersensitivity to peanut or soya should be monitored closely for signs of an allergic reaction.
Zato je treba bolnike z znano preobčutljivostjo na arašide ali sojo skrbno spremljati glede znakov alergijske reakcije.
Studies in animals have shown reproductive toxicity including teratogenic effects in rabbit without safety margin (see section 5.3).
Študije na živalih so pokazale vpliv na sposobnost razmnoževanja, vključno s teratogenimi učinki brez varnostne meje pri kuncih (glejte poglavje 5.3).
Do not take Akynzeo in the days after you have chemotherapy - unless you are about to have another chemotherapy cycle.
Zdravila Akynzeo ne vzemite v dneh po opravljeni kemoterapiji, razen če ste tik pred naslednjim načrtovanim ciklom kemoterapije.
Following administration of a single dose of Akynzeo, netupitant is eliminated from the body in a multi-exponential fashion, with an apparent mean elimination half-life of 88 hours in cancer patients.
Po dajanju enkratnega odmerka zdravila Akynzeo se netupitant izloča iz telesa na multieksponentni način, z navideznim povprečnim razpolovnim časom izločanja 88 ur pri bolnikih z rakom.
Because of the antiemetic activity of netupitant and palonosetron, emesis induced by a medicinal product may not be effective.
Zaradi antiemetičnega delovanja netupitanta in palonosetrona morda bruhanje, sproženo z zdravilom, ne bo učinkovito.
• medicines that might cause abnormal heartbeat such as amiodarone, nicardipine, quinidine,
• zdravila, ki lahko povzročijo nenormalen srčni utrip, kot so amiodaron, nikardipin, kinidin,
‘bundle branch block right/left', and ‘atrioventricular block second degree')
'desnokračni/levokračni blok' in 'atrioventrikularni blok druge stopnje').
• The other ingredients are microcrystalline cellulose (E460), sucrose lauric acid esters, povidone K-30, croscarmellose sodium, colloidal hydrated silica, sodium stearyl fumarate, magnesium stearate, glycerol monocaprylocaproate (type I), glycerol, polyglyceryl oleate, purified water, butylhydroxyanisole (E320), gelatin, sorbitol, 1,4 sorbitan, titanium dioxide (E171), shellac glaze (partially esterified), yellow, red and black iron oxide (E172), propylene glycol (E1520).
• Druge sestavine so mikrokristalna celuloza (E460), estri saharoze in lavrinske kisline, povidon K-30, premrežen natrijev karmelozat, hidratirani koloidni silicijev dioksid, natrijev stearilfumarat, magnezijev stearat, glicerol monokaprilat monokaprinat (tip I), glicerol, poligliceril oleat, prečiščena voda, butilhidroksianizol (E320), želatina, sorbitol, 1,4 sorbitan, titanov dioksid (E171), glazura iz šelaka (delno estrificiranega), rumeni, rdeči in črni železov oksid (E172), propilenglikol (E1520).
Co-administration of a single dose of 300 mg netupitant with a dexamethasone regimen (20 mg on Day 1, followed by 8 mg twice daily from Day 2 to Day 4) significantly increased the exposure to dexamethasone in a time and dose dependent manner.
Sočasno dajanje enkratnega 300 mg odmerka netupitanta ob režimu zdravljenja s deksametazonom (20 mg 1. dan, nato pa 8 mg dvakrat dnevno od 2. do 4. dne) je znatno povečalo izpostavljenost deksametazonu v odvisnosti od časa in odmerka.
These metabolites each have less than 1% of the 5-HT3 receptor antagonist activity of palonosetron.
Vsak od teh dveh presnovkov ima manj kot 1 % antagonističnega učinka na receptorje 5-HT3, ki ga ima palonosetron.
Mean Cmax was approximately 11%, 47% and 16% of the parent for M1, M2 and M3 respectively; M2 had the lowest AUC relative to the parent (14%) whereas M1 and M3 AUC were approximately 29% and 33% of the parent, respectively.
Povprečna Cmax za M1, M2 oziroma M3 je bila približno11 %, 47 % oziroma 16 % vrednosti izvorne spojine; M2 je imel najmanjšo AUC glede na izvorno spojino (14 %), medtem ko sta AUC presnovkov M1 in M3 dosegali približno 29 % in 33 % AUC izvorne spojine.
Netupitant and combination with palonosetron
Netupitant in kombinacija s palonosetronom
There are no data about the use of palonosetron in pregnant women.
Podatkov o uporabi palonosetrona pri nosečnicah ni.
Akynzeo contains sucrose, sorbitol, sodium and may contain traces of soya.
Zdravilo Akynzeo vsebuje saharozo, sorbitol, natrij in lahko vsebuje sledi soje.
Common adverse reactions reported with netupitant/palonosetron capsules were headache (3.6%), constipation (3.0%) and fatigue (1.2%).
Pogosti neželeni učinki, o katerih so poročali pri kapsulah netupitanta in palonosetrona, so bili glavobol (3,6 %), zaprtje (3,0 %) in utrujenost (1,2 %).
Based on the experience with healthy subjects exposed to oral netupitant 600 mg in combination with palonosetron 1.50 mg the potential acute symptoms of overdose are headache, dizziness, constipation, anxiety, palpitations, euphoric mood and pain in the legs.
Na podlagi izkušenj z zdravimi osebami, ki so bile izpostavljene peroralnemu netupitantu 600 mg v kombinaciji s palonosetronom 1,50 mg, so možni akutni simptomi prevelikega odmerjanja glavobol, omotica, zaprtje, anksioznost, palpitacije, evforično razpoloženje in bolečine v nogah.
• ECG (electrocardiogram) problems (called ‘QT and PR interval prolongation', ‘conduction disorder', ‘tachycardia' and ‘atrioventricular block first degree')
• težave v EKG (elektrokardiogramu) (ki jim pravimo 'podaljšanje intervala QT in PR', 'motnja prevajanja', 'tahikardija' in 'atrioventrikularni blok prve stopnje');
• spinning sensation (vertigo), feeling dizzy or trouble sleeping (insomnia)
• občutek vrtenja (vrtoglavica), občutek omotičnosti ali težave s spanjem (nespečnost);
The third major metabolite, M2, is > 97% bound to plasma proteins.
Tretji glavni presnovek M2 se več kot 97 % veže na beljakovine v plazmi.
Chemotherapy medicines can cause the body to release substances called serotonin and substance P. This stimulates the vomiting centre in the brain, making you feel or be sick.
Zdravila za kemoterapijo lahko povzročijo, da telo izloča snovi, ki jima pravimo serotonin in snov P. To spodbuja center v možganih, ki je odgovoren za bruhanje, zaradi česar vam je lahko slabo ali bruhate.
The AUC0-24 (Day 1), the AUC24-36 (Day 2) and the AUC84-108 and AUC84-∞ (Day 4) of dexamethasone increased 2.4-fold, with co-administration of 300 mg netupitant.
AUC0-24 (1. dan), AUC24-36 (2. dan) ter AUC84-108 in AUC84-∞ (4. dan) deksametazona povečale za 2,4-krat.
Approximately half the radioactivity administered orally as [14C]-netupitant was recovered from urine and faeces within 120 h of dosing.
Približno polovico radioaktivnosti, peroralno dane v obliki [14C]-netupitanta, so odkrili v urinu in blatu v 120 urah od odmerjanja.
• ECG (electrocardiogram) problems (called ‘ST segment depression', ‘ST-T segment abnormal'
• težave v EKG (imenujejo se 'depresija segmenta ST', 'nenormalen segment ST-T',
Therefore, patients should be monitored for increased toxicity of chemotherapeutic agents that are substrates for CYP3A4, including irinotecan.
Zaradi tega je treba bolnike spremljati glede povečane toksičnosti kemoterapevtskih zdravil, ki so substrati za CYP3A4, vključno z irinotekanom.
While the terminal elimination half-life and mean systemic exposure of palonosetron is increased in the subjects with severe hepatic impairment, this does not warrant dose reduction.
Čeprav sta končni razpolovni čas izločanja in povprečna sistemska izpostavljenost palonosetronu pri bolnikih s hudo okvaro jeter povečana, zaradi tega ni potrebna prilagoditev odmerka.
After a single oral 300 mg dose administration in cancer patients, netupitant disposition was characterised by a two compartment model with an estimated median systemic clearance of 20.5 L/h and a large distribution volume in the central compartment (486 L).
Po dajanju enkratnega peroralnega odmerka 300 mg pri bolnikih z rakom je bil za porazdelitev netupitanta značilen dvorazdelčni model z ocenjenim medianim sistemskim očistkom 20,5 l/uro in velikim volumnom porazdelitve v centralnem razdelku (486 l).
Table 3: Proportion of patients receiving cisplatin chemotherapy responding by treatment group and phase
Preglednica 3: Delež odziva bolnikov, ki so prejemali kemoterapijo s cisplatinom, po skupinah zdravljenja in fazah
In vitro data shows that netupitant inhibits UGT2B7, the magnitude of such an effect in the clinical setting is not established.
Podatki in vitro kažejo, da netupitant zavira UGT2B7, velikost tega učinka v kliničnih okoliščinah pa ni bila ugotovljena.
Upper 95% confidence limit of the point estimates of placebo and baseline corrected QTcI was constantly within 10 ms at all time points over 2 days after study substance administration.
Zgornja meja 95-% intervala zaupanja točkovnih ocen QTcI, korigiranih s placebom in izhodiščno vrednostjo, je bila stalno znotraj 10 ms v vseh časovnih točkah v 2 dneh po dajanju preučevane snovi.
The hard capsules are opaque with a white body and a caramel cap with ‘HE1' printed on the body.
Trde kapsule so neprozorne z belim telesom in pokrovčkom karamelne barve ter oznako »HE1«, odtisnjeno na telesu.
Opaque gelatin capsule of size “0” (length 21.7 mm) with white body and caramel cap with “HE1” printed on the body.
Neprozorna želatinasta kapsula velikosti »0« (dolžina 21,7 mm) z belim telesom in pokrovčkom karamelne barve ter oznako »HE1«, odtisnjeno na telesu.
Titanium dioxide (E171)
1,4 sorbitan titanov dioksid (E171)
Breast-feeding should be discontinued during treatment with this medicinal product and for 1 month after the last dose.
Med zdravljenjem s tem zdravilom in do 1 mesec po zadnjem odmerku je treba prenehati z dojenjem.
Effects in non-clinical studies based on safety pharmacology and single and repeated dose toxicity were observed only at exposures considered in excess of the maximum human exposure, indicating little relevance to clinical use.
V predkliničnih študijah na osnovi farmakologije varnosti ter toksičnosti enkratnih in ponavljajočih se odmerkov so učinke opazili samo pri izpostavljenosti, ki je presegala največjo izpostavljenost pri človeku, kar kaže na majhen pomen za klinično uporabo.
A total of 1450 patients (Akynzeo n=725; Palonosetron n=725) received study medication.
Preučevano zdravilo je prejelo skupno 1450 bolnikov (Akynzeo n = 725; palonosetron n = 725).
Following administration of a single oral 0.75 mg dose of [14C]-palonosetron to six healthy subjects, 85% to 93% of the total radioactivity was excreted in urine, and 5% to 8% was eliminated in faeces.
Po dajanju enkratnega peroralnega 0,75 mg odmerka [14C]-palonosetrona šestim zdravim osebam se je 85 % do 93 % celotne radioaktivnost izločilo v urin in 5 % do 8 % v blato.
The pharmacokinetic profile of netupitant was unchanged when administered in combination with dexamethasone.
Farmakokinetični profil netupitanta je bil ob dajanju v kombinaciji z deksametazonom nespremenjen.
Reproductive studies in animals with netupitant do not indicate direct or indirect harmful effects with respect to fertility, parturition or postnatal development.
Študije razmnoževanja z netupitantom na živalih ne kažejo neposrednih ali posrednih škodljivih učinkov na plodnost, kotitev ali postnatalni razvoj.
• conjunctivitis (a type of eye inflammation)
• konjuktivitis (vrsta vnetja očesa),
Acute psychosis Mood altered Sleep disorder
Psihiatrične motnje nespečnost akutna psihoza sprememba razpoloženja motnja spanja
Therefore, patients with known hypersensitivity to peanut or soya should be monitored closely for signs of an allergic reaction (see section 4.8).
Zaradi tega je treba bolnike z znano preobčutljivostjo na arašide ali sojo skrbno spremljati glede znakov alergijske reakcije (glejte poglavje 4.8).
Treatment regimens for the Akynzeo and the palonosetron 0.5 mg arms are displayed in Table below.
Režimi zdravljenja za kraka z zdravilom Akynzeo in palonosetronom 0,5 mg so prikazani v spodnji preglednici.
Delayed emesis has been associated with the activation of tachykinin family neurokinin 1 (NK1) receptors (broadly distributed in the central and peripheral nervous systems) by substance P. As shown in in vitro and in vivo studies, netupitant inhibits substance P mediated responses.
Zakasnjeno bruhanje povezujemo z aktivacijo receptorjev za nevrokinin 1 (NK1) iz družine tahikininov (ki so obsežno porazdeljeni po osrednjem in perifernem živčevju) s strani snovi P. Kot so dokazali v študijah in vitro in in vivo, netupitant zavira odzive, ki jih posreduje snov P.
This medicine contains less than 1 mmol sodium per (23 mg) per hard capsule, that is to say essentially ‘sodium-free'.
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na trdo kapsulo, kar v bistvu pomeni 'brez natrija'.
Very rare: may affect up to 1 in 10,000 people
Zelo redki: lahko se pojavijo pri največ 1 od 10.000 bolnikov
Table 5: Proportion of patients receiving anthracycline and cyclophosphamide chemotherapy responding by treatment group and phase - cycle 1
Preglednica 5: Delež odziva bolnikov, ki so prejemali kemoterapijo z antraciklinom in ciklofosfamidom, po skupinah zdravljenja in fazah - 1. cikel
• infection and inflammation in the bladder (cystitis)
• okužba in vnetje sečnega mehurja (cistitis),
What Akynzeo is and what it is used for What you need to know before you take Akynzeo How to take Akynzeo
Kaj je zdravilo Akynzeo in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Akynzeo Kako jemati zdravilo Akynzeo Možni neželeni učinki
• coating of the tongue, difficulty swallowing, dry mouth, belching, abnormal taste after medicine intake
• obložen jezik, težave s požiranjem, suha usta, kolcanje, nenormalen okus po jemanju zdravila;
• you have any other heart problems • you have been told you have an imbalance of minerals in your blood such as potassium and magnesium that has not been corrected.
• če so vam povedali, da imate neravnovesje mineralov (na primer kalija ali magnezija) v krvi, ki še ni urejeno.